

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume
NEWS 18 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 19 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 21 JUN 02 The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:37:39 ON 12 JUN 2006

| | | |
|--|---------------------|------------------|
| => file medline, biosis, wpids
COST IN U.S. DOLLARS | SINCE FILE
ENTRY | TOTAL
SESSION |
| FULL ESTIMATED COST | 0.42 | 0.42 |

FILE 'MEDLINE' ENTERED AT 12:38:49 ON 12 JUN 2006

FILE 'BIOSIS' ENTERED AT 12:38:49 ON 12 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 12:38:49 ON 12 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s ANG-1
L1 1700 ANG-1

=> s l1 and (ECM-binding domain)
L2 1 L1 AND (ECM-BINDING DOMAIN)

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
TI New pharmaceutical composition comprises a pharmaceutical carrier and an amount of an extracellular matrix (ECM)-binding fragment of **Ang-1** protein or a mutant **Ang-1**, useful for treating, e.g. cancer, vascular disease, or ischemia.
AN 2004-653413 [63] WPIDS
AB WO2004076650 A UPAB: 20041001
NOVELTY - A pharmaceutical composition comprising a pharmaceutical carrier and an amount of an extracellular matrix (ECM)-binding fragment of **Ang-1** protein or a mutant **Ang-1**, is new.

DETAILED DESCRIPTION - A pharmaceutical composition comprises a pharmaceutical carrier and:

(a) an amount of an ECM-binding fragment of **Ang-1** protein comprising 20-42 amino acids (SEQ ID NO. 1-4), or its homologous peptide and/or a vector comprising a nucleic acid molecule that encodes an ECM-binding fragment of **Ang-1** protein;

(b) an amount of a non-ECM binding fragment of **Ang-1** protein that comprises a modification in an **ECM-binding domain** of **Ang-1**, where the modification reduces the binding of **Ang-1** to an ECM and/or a vector comprising a nucleic acid molecule that encodes a non-ECM binding fragment of **Ang-1** protein that comprises a modification in an **ECM-binding domain** of **Ang-1**, where the modification reduces the binding of **Ang-1** to the ECM;

(c) an amount of a proteolytic resistant fragment of **Ang-1** protein that comprises a modification in a proteolytic domain of **Ang-1**, where the modification inhibits the proteolysis of **Ang-1** and/or a vector comprising a nucleic acid molecule that encodes a proteolytic resistant fragment of **Ang-1** protein that comprises a modification in a proteolytic domain of **Ang-1**, where the modification inhibits the proteolysis of **Ang-1**;

(d) an amount of a mutant **Ang-1** which retain their angiogenesis promoting activity but have reduced or inactive ECM binding or its homologous peptide or mutant versions of **Ang-1**

or a homologous peptide and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a mutant **Ang-1** which retain their angiogenesis promoting activity but have reduced or inactive ECM binding or a homologous peptide or mutant versions of **Ang-1**;

- (e) an amount of a mutant **Ang-1** which retain their angiogenesis promoting activity but which is not cleaved into an antagonist fragment or a homologous peptide and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that a mutant **Ang-1** which retain their angiogenesis promoting activity but has not cleaved into a antagonist fragment or a homologous peptide; or
- (f) an amount of an **Ang-1** fragment with antagonist activity and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of an **Ang-1** fragment with antagonist activity.

INDEPENDENT CLAIMS are also included for:

- (1) a method of treating an individual suspected of having coronary artery disease, vascular disease or a condition involving ischemia;
- (2) a method of promoting angiogenesis, endothelial survival and maintaining vascular integrity in an individual;
- (3) a method of treating an individual suspected of having a disease related to lack of blood vessels to effectively promote angiogenesis in the patients with the diseases related to lack of blood vessels such as ischemia in hearts and limbs;
- (4) a method to reduce stroke, heart attack, blood vessel blockage, hemorrhage, atherosclerosis risk by maintaining the health and integrity of blood vessels;
- (5) a method to assist the recovery of the patients who had stroke and the angioplasty procedure by promoting the growth/survival of endothelial cells and establish endothelial monolayer and inhibit excessive inflammation, hemorrhage, and proliferation of vascular smooth muscle;
- (6) a method to treat patients with restenosis by inhibiting re-closure of blood vessel after inserting stents into blood vessels;
- (7) a method to make stable and functional artificial blood vessels comprising using the composition above;
- (8) a method of identifying compounds that modulates binding of **Ang-1** to ECM;
- (9) a method of treating an individual suspected of having cancer;
- (10) a method of preventing diabetes and/or arthritis in an individual suspected of being at risk of developing diabetes or arthritis;
- (11) a fusion protein comprising:
 - (a) an ECM binding motif SEQ ID NO. 1-4 and a biologically active non-**Ang-1** protein;
 - (b) a non-ECM binding fragment of **Ang-1** and a biologically active non-**Ang-1** protein; or
 - (c) SEQ ID NO. 1-12 and non-**Ang-1** protein;
- (12) a method of diagnosing an elevated probability of metastatic disease following tumor removal or elimination;
- (13) a method of diagnosing and evaluating cancer in an individual for its probability of being an aggressive malignant cancer;
- (14) a method of inhibiting Erk1/2 phosphorylation in a cell comprising administering the pharmaceutical composition;
- (15) a method of inhibiting tumor angiogenesis in an animal; and
- (16) a nucleic acid molecule encoding a fusion protein SEQ ID NO. 1-12 and non-**Ang-1** protein.

ACTIVITY - Cytostatic; Vasotropic; Antidiabetic; Antiarthritic; Cerebroprotective; Antiangiogenic.

No biological data given.

MECHANISM OF ACTION - Gene Therapy.

USE - The pharmaceutical composition is useful for treating diseases and disorders, e.g. cancer, coronary artery disease, vascular disease, ischemia, restenosis, diabetes, stroke, angiogenesis, or arthritis.

Dwg.0/8

ACCESSION NUMBER: 2004-653413 [63] WPIDS
DOC. NO. CPI: C2004-233867
TITLE: New pharmaceutical composition comprises a pharmaceutical carrier and an amount of an extracellular matrix (ECM)-binding fragment of Ang-1 protein or a mutant Ang-1, useful for treating, e.g. cancer, vascular disease, or ischemia.
DERWENT CLASS: B04 D16
INVENTOR(S): YU, Q
PATENT ASSIGNEE(S): (YUQQ-I) YU Q; (UYPE-N) UNIV PENNSYLVANIA
COUNTRY COUNT: 108
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---------------|---|--------------------|------|-----|----|
| WO 2004076650 | A2 | 20040910 (200463)* | EN | 114 | |
| RW: | AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW | | | | |
| W: | AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW | | | | |
| US 2004186054 | A1 | 20040923 (200463) | | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---------------|----------------|-----------------|----------|
| WO 2004076650 | A2 | WO 2004-US6101 | 20040227 |
| US 2004186054 | A1 Provisional | US 2003-450582P | 20030227 |
| | | US 2004-789222 | 20040227 |

PRIORITY APPLN. INFO: US 2003-450582P 20030227; US
2004-789222 20040227

=> e yu,q/au

| | | |
|-----|---|-----------------|
| E1 | 2 | YU ZUXI/AU |
| E2 | 1 | YU ZUYUAN/AU |
| E3 | 0 | --> YU,Q/AU |
| E4 | 1 | YUA/AU |
| E5 | 1 | YUA L M/AU |
| E6 | 2 | YUA LIHUA/AU |
| E7 | 2 | YUA M/AU |
| E8 | 1 | YUA X/AU |
| E9 | 1 | YUABOV B M/AU |
| E10 | 1 | YUABOV YU M/AU |
| E11 | 3 | YUABOVA E YU/AU |
| E12 | 3 | YUABOVA M G/AU |

Refine Search

Search Results -

| Terms | Documents |
|-----------|-----------|
| L7 and L6 | 0 |

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Monday, June 12, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT; PLUR=YES; OP=OR

| | | | |
|-----------|-------------------------------------|-------|-----------|
| <u>L8</u> | L7 and l6 | 0 | <u>L8</u> |
| <u>L7</u> | yu.in. | 11653 | <u>L7</u> |
| <u>L6</u> | L5 and l4 | 38 | <u>L6</u> |
| <u>L5</u> | (TIE-2 ligand) | 66982 | <u>L5</u> |
| <u>L4</u> | Ang-1 | 210 | <u>L4</u> |
| <u>L3</u> | L1 and (pharmaceutical composition) | 1 | <u>L3</u> |
| <u>L2</u> | L1 and composition | 1 | <u>L2</u> |
| <u>L1</u> | 6441137.pn. | 1 | <u>L1</u> |

END OF SEARCH HISTORY

Hit List

Search Results - Record(s) 1 through 10 of 38 returned.

1. Document ID: US 7056509 B2

L6: Entry 1 of 38

File: USPT

Jun 6, 2006

US-PAT-NO: 7056509

DOCUMENT-IDENTIFIER: US 7056509 B2

TITLE: Antibody methods for selectively inhibiting VEGF

DATE-ISSUED: June 6, 2006

PRIOR-PUBLICATION:

DOC-ID DATE

US 20030175276 A1 September 18, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|---------|-------|----------|---------|
| Thorpe; Philip E. | Dallas | TX | | US |
| Brekken; Rolf A. | Seattle | WA | | US |

US-CL-CURRENT: 424/145.1; 424/130.1, 424/133.1, 424/184.1, 530/387.1, 530/388.1,
530/388.15, 530/388.25, 530/809, 530/864, 530/865, 530/866

2. Document ID: US 7052695 B2

L6: Entry 2 of 38

File: USPT

May 30, 2006

US-PAT-NO: 7052695

DOCUMENT-IDENTIFIER: US 7052695 B2

TITLE: Angiopoietins and methods of treating hypertension

DATE-ISSUED: May 30, 2006

PRIOR-PUBLICATION:

DOC-ID DATE

US 20030082177 A1 May 1, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|-----------|-------|----------|---------|
| Kalish; Susan Croll | Tarrytown | NY | | US |

US-CL-CURRENT: 424/178.1; 514/12, 530/388.22, 530/391.1

3. Document ID: US 7008781 B1

L6: Entry 3 of 38

File: USPT

Mar 7, 2006

US-PAT-NO: 7008781

DOCUMENT-IDENTIFIER: US 7008781 B1

TITLE: Method of enhancing the biological activity of ligands

DATE-ISSUED: March 7, 2006

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|------------------------|------------------|-------|----------|---------|
| Davis; Samuel | New York | NY | | US |
| Gale; Nicholas W. | Tarrytown | NY | | US |
| Yancopoulos; George D. | Yorktown Heights | NY | | US |
| Stahl; Neil | Carmel | NY | | US |

US-CL-CURRENT: 435/69.7; 424/134.1, 424/192.1, 435/252.33, 435/254.2, 435/320.1, 435/348,
435/360, 435/365.1, 514/12, 514/2, 530/399, 536/23.5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) |  | [Claims](#) | [KMM](#) | [Drawn Desc](#) | [Image](#)

4. Document ID: US 6962802 B2

L6: Entry 4 of 38

File: USPT

Nov 8, 2005

US-PAT-NO: 6962802

DOCUMENT-IDENTIFIER: US 6962802 B2

TITLE: Growth factor homolog ZVEGF4

DATE-ISSUED: November 8, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|----------------------|---------------|-------|----------|---------|
| Gilbert; Teresa | Seattle | WA | | |
| Hart; Charles E. | Woodinville | WA | | |
| Sheppard; Paul O. | Granite Falls | WA | | |
| Gilbertson; Debra G. | Seattle | WA | | |

US-CL-CURRENT: 435/69.4; 435/320.1, 435/69.1, 530/350, 530/399, 536/23.1, 536/23.5,
536/23.51

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) |  | [Claims](#) | [KMM](#) | [Drawn Desc](#) | [Image](#)

5. Document ID: US 6958147 B1

L6: Entry 5 of 38

File: USPT

Oct 25, 2005

US-PAT-NO: 6958147

DOCUMENT-IDENTIFIER: US 6958147 B1

TITLE: Use of VEGF-C to prevent restenosis

DATE-ISSUED: October 25, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|----------------------|-----------------|-------|----------|---------|
| Alitalo; Kari | Espoo | | | FI |
| Yla-Herttuala; Seppo | Kuopio | | | FI |
| Hiltunen; Mikko O. | Kuopio | | | FI |
| Jeltsch; Markku M. | Helsinki | | | FI |
| Achen; Marc G. | North Melbourne | | | AU |

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.21, 435/320.1, 435/325, 435/455, 435/69.1,
514/44, 536/23.1, 536/23.5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Drawn Desc](#) | [Ima](#)

□ 6. Document ID: US 6947845 B2

L6: Entry 6 of 38

File: USPT

Sep 20, 2005

US-PAT-NO: 6947845

DOCUMENT-IDENTIFIER: US 6947845 B2

TITLE: Method of identifying molecules that bind to the large ribosomal subunit

DATE-ISSUED: September 20, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|-------------|-------|----------|---------|
| Steitz; Thomas A. | Branford | CT | | |
| Moore; Peter B. | North Haven | CT | | |
| Ippolito; Joseph A. | Guilford | CT | | |
| Ban; Nenad | Zurich | | | CH |
| Nissen; Poul | Aarhus | | | DE |
| Hansen; Jeffrey L. | Charleston | SC | | |

US-CL-CURRENT: 702/19; 702/20, 702/27

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Drawn Desc](#) | [Ima](#)

□ 7. Document ID: US 6943153 B1

L6: Entry 7 of 38

File: USPT

Sep 13, 2005

US-PAT-NO: 6943153

DOCUMENT-IDENTIFIER: US 6943153 B1

TITLE: Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

DATE-ISSUED: September 13, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------------|--------------|-------|----------|---------|
| Manning, Jr.; William C. | Redwood City | CA | | |
| Dwarki; Varavani J. | Pittstown | NJ | | |
| Rendahl; Katherine | Berkeley | CA | | |
| Zhou; Shangzhen | Alameda | CA | | |

Miller; Sheldon S. Berkeley CA
Wang; Fei Albany CA

US-CL-CURRENT: 514/44; 424/233.1, 424/93.21

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) |  |  | [Claims](#) | [KINIC](#) | [Drawn Desc](#) | [Imgs](#)

8. Document ID: US 6943146 B2

L6: Entry 8 of 38

File: USPT

Sep 13, 2005

US-PAT-NO: 6943146
DOCUMENT-IDENTIFIER: US 6943146 B2


TITLE: Method for promoting neovascularization

DATE-ISSUED: September 13, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|-------------|-------|----------|---------|
| Jakubowski; Aniela | Arlington | MA | | |
| Burkly; Linda | West Newton | MA | | |

US-CL-CURRENT: 514/12; 424/1.41, 530/350

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) |  |  | [Claims](#) | [KINIC](#) | [Drawn Desc](#) | [Imgs](#)

9. Document ID: US 6887468 B1

L6: Entry 9 of 38

File: USPT

May 3, 2005

US-PAT-NO: 6887468
DOCUMENT-IDENTIFIER: US 6887468 B1

TITLE: Antibody kits for selectively inhibiting VEGF

DATE-ISSUED: May 3, 2005

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|---------|-------|----------|---------|
| Thorpe; Philip E. | Dallas | TX | | |
| Brekken; Rolf A. | Seattle | WA | | |

US-CL-CURRENT: 424/130.1; 424/139.1, 424/143.1, 424/145.1, 530/388.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) |  |  | [Claims](#) | [KINIC](#) | [Drawn Desc](#) | [Imgs](#)

10. Document ID: US 6878729 B2

L6: Entry 10 of 38

File: USPT

Apr 12, 2005

US-PAT-NO: 6878729
DOCUMENT-IDENTIFIER: US 6878729 B2

TITLE: Medicinal uses of dihydropyrazoles

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------------|------------|-------|----------|---------|
| Almstead; Ji-In Kim | Holmdel | NJ | | |
| Izzo; Nicholas John | Pittsburgh | PA | | |
| Jones; David Robert | Milford | OH | | |
| Kawamoto; Richard Masaru | Lebanon | OH | | |

US-CL-CURRENT: 514/341; 546/275.4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Ima](#)

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

| Terms | Documents |
|-----------|-----------|
| L5 and L4 | 38 |

Display Format: [CIT](#) | [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)